AlhazzaniWMøllerMHArabiYMSurviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)Intensive Care Med.202046854–88710.1007/s00134-020-06022-5
2.
AlíaIEstebanACorrection: Weaning from mechanical ventilationJ Crit Care.200610441410.1186/cc4996
3.
AmatoMBBarbasCSMedeirosDMEffect of a protective-ventilation strategy on mortality in the acute respiratory distress syndromeN Engl J Med.1998338347–354 1:STN:280:DyaK1c7ht1ejtw%3D%3D 10.1056/NEJM199802053380602
4.
BaigAMKhaleeqAAliUSyedaHEvidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanismsACS Chem Neurosci.2020117995–998 1:CAS:528:DC%2BB3cXkslGrs70%3D 10.1021/acschemneuro.0c00122 32167747 7094171
5.
BeigelJH, TomashekKM, DoddLE, et al. Remdesivir for the treatment of Covid-19—preliminary report [published online ahead of print, 2020 May 22].N Engl J Med. 2020;https://doi.org/10.1056/NEJMoa2007764.
6.
BernardGRArtigasABrighamKLThe American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordinationAm J Respir Crit Care Med.19941493 pt 1818–824 1:STN:280:DyaK2c7mtlCnsA%3D%3D 10.1164/ajrccm.149.3.7509706
BoussugesABlancPMolenatFEvaluation of left ventricular filling pressure by transthoracic Doppler echocardiography in the intensive care unitCrit Care Med.200230362–36710.1097/00003246-200202000-00016
9.
BrowerRMatthayMMorrisAAcute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndromeN Engl J Med.20003421301–130810.1056/NEJM200005043421801
10.
CaoBWangYWenDA trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19N Engl J Med.2020382191787–179910.1056/NEJMoa200128232187464
11.
Carod-ArtalFJNeurological complications of coronavirus and COVID-19. Complicaciones neurológicas por coronavirus y COVID-19Rev Neurol2020709311–322 1:STN:280:DC%2BB38zptVKhsw%3D%3D 10.33588/rn.7009.202017932329044
12.
ChoyKTWongAYKaewpreedeePRemdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitroAntiviral Res.2020178104786 1:CAS:528:DC%2BB3cXntVOhtLw%3D 10.1016/j.antiviral.2020.104786 32251767 7127386
13.
CombesAHajageDExtracorporeal membrane oxygenation for severe acute respiratory distress syndromeN Engl J Med.2018378211965–197510.1056/NEJMoa1800385
14.
ConnorsJMLevyJHCOVID-19 and its implications for thrombosis and anticoagulationBlood.2020135232033–2040 1:CAS:528:DC%2BB3cXhtlSjs7nJ 10.1182/blood.2020006000 32339221 7273827
DurvasulaRWellingtonTMcNamaraEWatnickSCOVID-19 and kidney failure in the acute care setting: our experience from SeattleAm J Kidney Dis.20207614–6 1:CAS:528:DC%2BB3cXotFCgurw%3D 10.1053/j.ajkd.2020.04.001 32276031 7141473
18.
FamousKRDelucchiKWareLBAcute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategyAm J Respir Crit Care Med.2017195331–338 1:CAS:528:DC%2BC1cXjt1Sltbo%3D 10.1164/rccm.201603-0645OC
19.
FilatovASharmaPHindiFEspinosaPSNeurological complications of coronavirus disease (COVID-19): encephalopathyCureus.2020123e735210.7759/cureus.7352 32328364 7170017
20.
GattinoniLChiumelloDCaironiPCOVID-19 pneumonia: different respiratory treatments for different phenotypes?Intensive Care Med.20204661099–1102 1:CAS:528:DC%2BB3cXnsVait70%3D 10.1007/s00134-020-06033-232291463
21.
GautretPLagierJCParolaPHydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInt J Antimicrob Agents.2020561105949 1:CAS:528:DC%2BB3cXhsVOqt7vE 10.1016/j.ijantimicag.2020.105949 32205204 7102549
22.
GelerisJSunYPlattJObservational study of hydroxychloroquine in hospitalized patients with Covid-19N Engl J Med.2020382252411–2418 1:CAS:528:DC%2BB3cXht1Gmsb3N 10.1056/NEJMoa2012410
GoldmanJD, LyeDCB, HuiDS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19 [published online ahead of print, 2020 May 27].N Engl J Med. 2020;NEJMoa2015301. https://doi.org/10.1056/NEJMoa2015301.
25.
GordonDEJangGMBouhaddouMA SARS-CoV-2 protein interaction map reveals targets for drug repurposingNature.20205837816459–468 1:CAS:528:DC%2BB3cXhtlCqtbrI 10.1038/s41586-020-2286-9 32353859 7431030
26.
GoyalPChoiJJPinheiroLCClinical characteristics of Covid-19 in New York CityN Engl J Med.2020382242372–237410.1056/NEJMc201041932302078
27.
GuanWNiZHuYClinical characteristics of coronavirus disease 2019 in ChinaN Engl J Med.2020382181708–1720 1:CAS:528:DC%2BB3cXovVSjsb8%3D 10.1056/NEJMoa200203232109013
28.
GuérinCReignierJRichardJProne positioning in severe acute respiratory distress syndromeN Engl J Med.2013368232159–216810.1056/NEJMoa1214103
29.
HelmsJKremerSMerdjiHNeurologic features in Severe SARS-CoV-2 infectionN Engl J Med.2020382232268–227010.1056/NEJMc200859732294339
30.
HelmsJTacquardCSeveracFHigh risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort studyIntensive Care Med.20204661089–1098 1:CAS:528:DC%2BB3cXosVyktbc%3D 10.1007/s00134-020-06062-x
31.
HenryBMLippiGPoor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis of early reportsJ Crit Care.20205827–28 1:CAS:528:DC%2BB3cXmvFGqt7Y%3D 10.1016/j.jcrc.2020.03.011
32.
HungIFLungKCTsoEYTriple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trialLancet.2020395102381695–1704 1:CAS:528:DC%2BB3cXovFOjsr0%3D 10.1016/S0140-6736(20)31042-4 32401715 7211500
33.
JinMTongQRhabdomyolysis as potential late complication associated with 2019 novel coronavirus diseaseEmerg Infect Dis.20202671618–1620 1:CAS:528:DC%2BB3cXitlOlsbvM 10.3201/eid2607.200445 32197060 7323559
34.
KimD, QuinnJ, PinskyB, ShahNH, BrownI. Rates of co-infection between SARS-CoV-2 and other respiratory pathogens [published online ahead of print, 2020 Apr 15].JAMA. 2020;323(20):2085–2086. https://doi.org/10.1001/jama.2020.6266.
35.
KimmigL, WuD, GoldM, et al. IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections [preprint posted online, 2020 May 20]. medRxiv. 2020. 05.15.20103531. https://doi.org/10.1101/2020.05.15.20103531.
36.
KindlerEThielVWeberFInteraction of SARS and MERS coronaviruses with the antiviral interferon responseAdv Virus Res.201696219–243 1:CAS:528:DC%2BB3cXhsFGrtrnM 10.1016/bs.aivir.2016.08.006 27712625 7112302
37.
KlokFAKruipMJHAvan der MeerNJMIncidence of thrombotic complications in critically ill ICU patients with COVID-19Thromb Res.2020191145–147 1:CAS:528:DC%2BB3cXntVOjs7k%3D 10.1016/j.thromres.2020.04.013 32291094 7146714
38.
LaxSF, SkokK, ZechnerP, et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series [published online ahead of print, 2020 May 14].Ann Intern Med. 2020;M20-2566. https://doi.org/10.7326/M20-2566.
39.
LiXGuoZLiBExtracorporeal membrane oxygenation for coronavirus disease 2019 in Shanghai, ChinaASAIO J.2020665475–481 1:CAS:528:DC%2BB3cXnvFKltbg%3D 10.1097/MAT.0000000000001172 32243266 7273861
40.
LiuJCaoRXuMHydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitroCell Discov2020616 1:CAS:528:DC%2BB3cXltFChsrc%3D 10.1038/s41421-020-0156-0 32194981 7078228Published 2020 Mar 18
41.
MaatmanTK, JalaliF, FeizpourC, et al. Routine venous thromboembolism prophylaxis may be inadequate in the hypercoagulable state of severe coronavirus disease 2019 [published online ahead of print, 2020 May 27].Crit Care Med. 2020. https://doi.org/10.1097/CCM.0000000000004466.
42.
MahévasMTranVTRoumierMClinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data [published correction appears in BMJ. 2020 Jun 18;369:m2328]BMJ2020369m184410.1136/bmj.m1844 32409486 7221472
43.
MaoLJinHWangMNeurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China [published online ahead of print, 2020 Apr 10]JAMA Neurol.20207761–910.1001/jamaneurol.2020.11277149362
44.
MariniJJ, GattinoniL. Management of COVID-19 respiratory distress [published online ahead of print, 2020 Apr 24].JAMA. 2020;https://doi.org/10.1001/jama.2020.6825.
MauriT, SpinelliE, ScottiE, et al. Potential for lung recruitment and ventilation-perfusion mismatch in patients with the acute respiratory distress syndrome from coronavirus disease 2019 [published online ahead of print, 2020 Apr 17].Crit Care Med. 2020. https://doi.org/10.1097/CCM.0000000000004386.
MontalvanVLeeJBuesoTDe ToledoJRivasKNeurological manifestations of COVID-19 and other coronavirus infections: a systematic reviewClin Neurol Neurosurg.2020194105921 1:STN:280:DC%2BB38votlygtg%3D%3D 10.1016/j.clineuro.2020.105921 32422545 7227498
49.
MoriguchiTHariiNGotoJA first case of meningitis/encephalitis associated with SARS-Coronavirus-2Int J Infect Dis.20209455–58 1:CAS:528:DC%2BB3cXnsVajtLg%3D 10.1016/j.ijid.2020.03.062 32251791 7195378
50.
MossJHLanctôtKLIatrogenic benzodiazepine withdrawal delirium in hospitalized older patientsJ Am Geriatr Soc.19984681020–1022 1:STN:280:DyaK1czntVeqsA%3D%3D 10.1111/j.1532-5415.1998.tb02761.x9706895
51.
NileSHNileAQiuJLiLJiaXKaiGCOVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferonsCytokine Growth Factor Rev.20205366–70 1:CAS:528:DC%2BB3cXpsVKrsLs%3D 10.1016/j.cytogfr.2020.05.002 32418715 7204669
52.
PisaniMAMurphyTEAraujoKLSlattumPVan NessPHInouyeSKBenzodiazepine and opioid use and the duration of intensive care unit delirium in an older populationCrit Care Med.2009371177–183 1:CAS:528:DC%2BD1cXhsFCnu7vE 10.1097/CCM.0b013e318192fcf9 19050611 2700732
RanieriVMSuterPMTortorellaCEffect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trialJAMA.199928254–61 1:STN:280:DyaK1MzjtFOqug%3D%3D 10.1001/jama.282.1.54
56.
RanucciMBallottaADi DeddaUThe procoagulant pattern of patients with COVID-19 acute respiratory distress syndromeJ Thromb Haemost.20201871747–1751 1:CAS:528:DC%2BB3cXhtlehu7%2FF 10.1111/jth.1485432302448
57.
RECOVERY Collaborative Group, HorbyP, LimWS, et al. Dexamethasone in hospitalized patients with Covid-19-preliminary report [published online ahead of print, 2020 Jul 17].N Engl J Med.2020;NEJMoa2021436. https://doi.org/10.1056/NEJMoa2021436
58.
RivaL, YuanS, YinX, et al. A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals [preprint published online 2020 Apr 16].bioRxiv. 2020;2020.04.16.044016. https://doi.org/10.1101/2020.04.16.044016.
59.
RussellCDMillarJEBaillieJKClinical evidence does not support corticosteroid treatment for 2019-nCoV lung injuryLancet.202039510223473–475 1:CAS:528:DC%2BB3cXisFaksr4%3D 10.1016/S0140-6736(20)30317-2 32043983 7134694
60.
SearcyRJMoralesJRFerreiraJAThe role of inhaled prostacyclin in treating acute respiratory distress syndromeTher Adv Respir Dis.20159302–312 1:CAS:528:DC%2BC28XnslOkt74%3D 10.1177/1753465815599345
61.
SedaghatZKarimiNGuillain Barre syndrome associated with COVID-19 infection: A case reportJ Clin Neurosci.202076233–235 1:CAS:528:DC%2BB3cXns1WrsL4%3D 10.1016/j.jocn.2020.04.062 32312628 7158817
62.
SteardoLSteardoLZorecRVerkhratskyANeuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19Acta Physiol (Oxf).20202293e13473 1:CAS:528:DC%2BB3cXmvVCgsbg%3D 10.1111/apha.1347332223077
TangNLiDWangXSunZAbnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumoniaJ Thromb Haemost.202018844–847 1:CAS:528:DC%2BB3cXlvV2ns70%3D 10.1111/jth.14768 32073213 7166509
66.
TangWCaoZHanMHydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trialBMJ.2020369m184910.1136/bmj.m1849 32409561 7221473
67.
ThachilJTangNGandoSISTH interim guidance on recognition and management of coagulopathy in COVID-19J Thromb Haemost.2020181023–1026 1:CAS:528:DC%2BB3cXotlSjsrk%3D 10.1111/jth.1481032338827
68.
TisoncikJRKorthMJSimmonsCPInto the eye of the cytokine stormMicrobiol Mol Biol Rev.201276116–32 1:CAS:528:DC%2BC38XlslKisb4%3D 10.1128/MMBR.05015-11
69.
ToscanoGPalmeriniFRavagliaSGuillain–Barré Syndrome Associated with SARS-CoV-2N Engl J Med.2020382262574–257610.1056/NEJMc200919132302082
70.
TremblayLValenzaFRibeiroSPInjurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung modelJ Clin Invest.199799944–952 1:CAS:528:DyaK2sXhs1Kqtbg%3D 10.1172/JCI119259
ValkSJPiechottaVChaiKLConvalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid reviewCochrane Database Syst Rev.202055CD01360010.1002/14651858.CD01360032406927
73.
VinetzJMLack of efficacy of hydroxychloroquine in COVID-19BMJ.2020369m201810.1136/bmj.m201832430461
74.
WangCLiWDrabekDA human monoclonal antibody blocking SARS-CoV-2 infection [published correction appears in Nat Commun. 2020 May 14;11(1):2511]Nat Commun20201112251 1:CAS:528:DC%2BB3cXovVChtrw%3D 10.1038/s41467-020-16256-y 32366817 7198537
75.
WangDHuBHuCClinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China [published online ahead of print, 2020 Feb 7]JAMA.2020323111061–1069 1:CAS:528:DC%2BB3cXlvVSqtbY%3D 10.1001/jama.2020.1585 32031570 7042881
76.
WangJHajizadehNMooreEETissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case seriesJ Thromb Haemost.20201871752–1755 1:CAS:528:DC%2BB3cXhtlehu7zN 10.1111/jth.1482832267998
77.
WangMCaoRZhangLRemdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Res.2020303269–271 1:CAS:528:DC%2BB3cXkt1Ciu7k%3D 10.1038/s41422-020-0282-0 32020029 32020029
78.
WestonS, ColemanC, HauptR, et al. Broad anticoronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo [preprint published online 25 Mar 2020].bioRxiv. 2020.03.25.008482.
79.
WiedemannHP, WheelerAP, BernardGR, et al. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network.Comparison of two fluid-management strategies in acute lung injury.N Engl J Med. 2006;354(24):2564–2575. https://doi.org/10.1056/NEJMoa062200.
80.
WinklerAMKoepsellSAThe use of convalescent plasma to treat emerging infectious diseases: focus on Ebola virus diseaseCurr Opin Hematol.2015226521–526 1:CAS:528:DC%2BC2MXhs1Kku77F 10.1097/MOH.0000000000000191
81.
WuYXuXChenZNervous system involvement after infection with COVID-19 and other coronavirusesBrain Behav Immun.20208718–22 1:CAS:528:DC%2BB3cXmvFKmurw%3D 10.1016/j.bbi.2020.03.031 32240762 7146689
82.
ZiehrDR, AlladinaJ, PetriCR, et al. Respiratory pathophysiology of mechanically ventilated patients with COVID-19: a cohort study.Am J Respir Crit Care Med. 2020. https://doi.org/10.1164/rccm.202004-1163LE.
